In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The early impact of gestational diabetes, hypertensive disorders of pregnancy, and obesity appears to grow as kids age.

The findings highlight the importance of rheumatology, cardiology, and primary care working together to intervene early.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...